The quarter came in below the standing earnings bar. Adjusted diluted EPS was $1.48 versus the published consensus of roughly $1.50, while revenue net of excise taxes rose just 1.2% to $5.36 billion; external estimates also pointed to a modest revenue shortfall.
| Metric | Q2 2026 | Q2 2025 | Change | Expectation |
|---|---|---|---|---|
| Adjusted diluted EPS | $1.48 | $1.44 | 2.8% | ~$1.50 consensus |
| Net revenues | $6,111M | $6,102M | 0.1% | Below consensus |
| Revenues net of excise taxes | $5,356M | $5,294M | 1.2% | Below consensus |
| Smokeable products net revenues | $5,392M | $5,357M | 0.7% | — |
| Oral tobacco products net revenues | $713M | $753M | (5.3)% | — |
| Oral tobacco adjusted OCI | $460M | $500M | (8.0)% | — |
| Full-year adjusted EPS guidance | $5.61–$5.72 | $5.42 base | 3.5%–5.5% growth | Prior range $5.56–$5.72 |
The core cigarette business was resilient, but not enough to carry the quarter. Smokeable-products adjusted operating companies income increased 2.4% and margin expanded 0.3 percentage points, despite domestic cigarette volume falling 3.2%; pricing and tax refunds did most of the work. That performance was partly offset by Marlboro volume down 7.4% and total Marlboro retail share down 1.5 points. (Smokeable Products: Revenues and OCI; Reported Shipment Volume; Domestic Cigarettes Retail Share)
Oral tobacco was the clear operational miss. Segment revenue fell 5.3%, adjusted operating income dropped 8.0%, and adjusted margin contracted 2.0 points to 66.7%. Total oral shipment volume declined 8.5%, while Copenhagen and Skoal lost meaningful share; on! gained sequentially but still held only 14.4% of the nicotine-pouch category. The smoke-free growth narrative therefore remains narrower than management’s headline framing suggests. (Oral Tobacco Products: Revenues and OCI; Reported Shipment Volume; Retail Share)
Management improved the floor of the full-year outlook, but the ceiling did not move. Adjusted EPS guidance was narrowed to $5.61–$5.72 from $5.56–$5.72, effectively raising only the low end rather than increasing the midpoint. That is a modest constructive revision, but it does not erase the quarterly miss. At the same time, planned capital spending rose to $375–$450 million from $300–$375 million to fund the USSTC manufacturing consolidation. (2026 Full-Year Guidance)
Net: a modest earnings miss with a small guidance cushion, not a clean beat. Adjusted EPS grew 2.8%, but the result fell short of consensus, oral tobacco deteriorated materially, and the higher guidance floor was accompanied by higher capital spending. The filing reshapes the picture toward dependable smokeable-product cash generation doing more of the work while the smoke-free transition remains under pressure. (Financial Highlights; Smokeable Products: Revenues and OCI; Oral Tobacco Products: Revenues and OCI; 2026 Full-Year Guidance)
Read the original 8-K on SEC EDGAR ↗